Mr. Chen took over as BlackBerry Ltd (NASDAQ:BBRY) new CEO last November, so will appear on next year’s compensation chart after the company files its pay disclosure for its 2014 fiscal year ended March 1, 2014. BlackBerry Ltd (NASDAQ:BBRY) net profit margin is -6.73% and weekly performance is 4.40%. On last trading day company shares ended up $7.60. Analysts mean target price for the company is $10.90. BlackBerry Ltd (NASDAQ:BBRY) distance from 50-day simple moving average (SMA50) is -2.54%.
Immunomedics, Inc., (NASDAQ:IMMU) reported the development of bispecific antibodies that redirect human T-cells to certain solid cancers. Immunomedics, Inc. (NASDAQ:IMMU) shares fell -4.03% in last trading session and ended the day on $3.33. IMMU gross Margin is 83.70% and its return on assets is -30.90%.Immunomedics, Inc. (NASDAQ:IMMU) quarterly performance is -29.75%.
Daxor Corporation, (NYSEMKT:DXR) an investment company with medical instrumentation and biotechnology operations announced on 30 April that its Idant Laboratories subsidiary has once again been granted accreditation by the American Association of Blood Banks (AABB) for the collection, freezing and storage of one’s own blood. Idant Laboratories is a pioneer in blood banking, and was the first laboratory registered to provide long-term self-storage of blood to the public. Daxor Corporation (NYSEMKT:DXR) shares moved down -0.64% in last trading session and was closed at $7.72, while trading in range of $7.72 – $7.72. Daxor Corporation (NYSEMKT:DXR) year to date (YTD) performance is 13.03%.
On May 19, 2014, Endocyte, Inc. (NASDAQ:ECYT) issued a press release, along with Merck, announcing the withdrawal of conditional marketing authorization applications from the European Medicines Agency for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer (“PROC”), in combination with pegylated liposomal doxorubicin. Endocyte, Inc. (NASDAQ:ECYT) ended the last trading day at $6.33. Company weekly volatility is calculated as 3.53% and price to cash ratio as 2.12.Endocyte, Inc. (NASDAQ:ECYT) showed a negative weekly performance of -1.86%.
C.R. Bard Inc. (NYSE:BCR) and the Vanderbush Family received Best Friend Awards, while Mary Ann Reilly received the Parent Guardian Award and Thomas Horn was given the 2014 Volunteer of the Year Award. C.R. Bard, Inc. (NYSE:BCR) net profit margin is 26.50% and weekly performance is 1.14%. On last trading day company shares ended up $147.91. Analysts mean target price for the company is $145.87. C.R. Bard, Inc. (NYSE:BCR) distance from 50-day simple moving average (SMA50) is 3.26%.